Company Announcement no. 1/2010

To: NASDAQ OMX Copenhagen A/S Hørsholm, Denmark, January 18, 2010

LifeCycle Pharma Announces Senior Management Hires and Refocus of the
Organization

LifeCycle Pharma A/S (OMX:LCP) today announced plans to refocus its
organization to optimize value creation. The key focus of LCP continues to be
on the phase 3 development, and later registration in major markets, of
LCP-TacroTM, LCP's product candidate for the prevention of organ rejection.
Further, LCP continuously aims to create external partnerships on LCP's other
pipeline projects, as well as strategic partnerships related to LCP's
technologies, including LCP's proprietary technology, Meltdose®.

LCP will strengthen its organization in the areas of late stage development and
business development during the first half of 2010 with up to 10 new employees.
LCP has in this regard recruited Tim Melkus as Senior Vice President
Development Operations to head clinical functions and development operations,
including project planning, and Ronald Guido as Vice President Regulatory
Affairs to head the strategic and operational regulatory work at LCP. Tim
Melkus most recently worked as Senior Vice President, Business Development and
Operations at IDM Pharma, while Ronald Guido joins from a position as Senior
Director, Regulatory Affairs which included strategic oversight of
cardiovascular and other regulatory activities at Pfizer, Inc. Mr. Melkus and
Mr. Guido will be based in LCP's office in the U.S., which shortly will be
relocated to New Jersey from New York City.

As a consequence of LCP-Tacro? having completed early development, LCP plans to
reduce its organization by up to 30 employees in the area of CMC (Chemistry,
Manufacturing and Control) and in LCP's administrative functions.

The financial impact for 2010 of these changes will be announced on February
24, 2010 in connection with the issuance of the Annual Report for 2009. The
changes are expected to reduce LCP's cost base during 2010, and significantly
in 2011 and onwards, compared to previous expectations, thus LCP's net cash
position will be extended from earlier around year end 2010 into the second
quarter of 2011.

For more information, please contact:

LifeCycle Pharma A/S
William J. Polvino Peter Schøtt Knudsen
President and CEO Head of Investor Relations
Phone: + 45 70 33 33 00 Phone: + 45 20 55 38 17
Email: [email protected] Email: [email protected]

For further information, please also visit www.lcpharma.com.

lifecycle pharma announce refocusing 18012010.pdf